Joel Greenblatt Bristol Myers Squibb CO Transaction History

Gotham Asset Management, LLC

$6.49 Billion
Q1 2024

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Gotham Asset Management, LLC holds 346,210 shares of BMY stock, worth $14.2 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

346,210

Previous 259,150 33.59%

Holding current value

$14.2 Million

Previous $13.3 Million 41.2%

% of portfolio

0.29%

Previous 0.25%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $4.18 Million - $4.74 Million	87,060 Added 33.59%	346,210 $18.8 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $2.51 Million - $2.99 Million	51,745 Added 24.95%	259,150 $13.3 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $3.02 Million - $3.37 Million	52,110 Added 33.56%	207,405 $12 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $4.04 Million - $4.49 Million	63,449 Added 69.08%	155,295 $9.93 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $6.08 Million - $6.89 Million	-92,512 Reduced 50.18%	91,846 $6.37 Million

Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $888,322 - $1.05 Million	12,972 Added 7.57%	184,358 $13.3 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $5,948 - $3.52 Million	45,754 Added 36.42%	171,386 $12.2 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $1.33 Million - $1.47 Million	18,383 Added 17.14%	125,632 $9.67 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $435,770 - $522,527	7,088 Added 7.08%	107,249 $7.83 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $288,583 - $336,420	5,381 Added 5.68%	100,161 $6.25 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $5.34 Million - $6.25 Million	90,217 Added 1977.14%	94,780 $5.61 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $282,495 - $307,637	4,563 New	4,563 $305,000
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $3.95 Million - $4.44 Million	-66,597 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $4.27 Million - $4.84 Million	-74,004 Reduced 52.63%	66,597 $4.13 Million
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $12.6 Million - $14 Million	-219,426 Reduced 60.95%	140,601 $8.48 Million
Q2 2020 Aug 13, 2020	BUY	$54.82 - $64.09 $5.2 Million - $6.08 Million	94,928 Added 35.81%	360,027 $21.2 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $32.5 Million - $47.2 Million	-699,364 Reduced 72.51%	265,099 $14.8 Million
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $2.99 Million - $3.9 Million	-60,747 Reduced 5.93%	964,463 $61.9 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $10.1 Million - $11.9 Million	-235,538 Reduced 18.68%	1,025,210 $52 Million
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $15.2 Million - $16.8 Million	340,589 Added 37.01%	1,260,748 $57.2 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $30.6 Million - $36.5 Million	679,164 Added 281.82%	920,159 $43.9 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $2.24 Million - $2.91 Million	45,990 Added 23.58%	240,995 $12.5 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $5.59 Million - $6.31 Million	-101,296 Reduced 34.19%	195,005 $12.1 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $13.8 Million - $17.2 Million	273,224 Added 1183.97%	296,301 $16.4 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $7.89 Million - $9.09 Million	-131,716 Reduced 85.09%	23,077 $1.46 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $1.99 Million - $2.17 Million	33,199 Added 27.3%	154,793 $9.49 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $6.72 Million - $7.75 Million	121,594	121,594 $7.75 Million

Others Institutions Holding BMY

# of Institutions

2,554

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $87.1B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account